Sarepta Therapeutics (SRPT) Gains on Coverage Update
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Sarepta Therapeutics (NASDAQ: SRPT) active as Anthem is said to be out positive now on Etep coverage.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Defends Corbus Pharmaceuticals (CRBP) Following Short Report
- Michael Kors (KORS) volatility flat on tight four-month trading range
- Dipexium Pharma (DPRX) Resumes Trading Following LUDP Halt
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!